BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 1700860)

  • 1. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
    Buamah PK; Johnson P; Skillen AW
    Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
    van Dieijen-Visser MP; Hendriks MW; Delaere KP; Gijzen AH; Brombacher PJ
    Clin Chim Acta; 1988 Sep; 177(1):77-80. PubMed ID: 2460272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker.
    Leitenberger A; Altwein JE
    Eur Urol; 1990; 17(1):12-6. PubMed ID: 1690653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J; de Torres Mateos JA
    Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
    Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
    Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
    Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
    Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
    Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice.
    Daver A; Soret JY; Coblentz Y; Allain YM; Cellier P; Chauveau P
    Am J Clin Oncol; 1988; 11 Suppl 2():S53-60. PubMed ID: 2468273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: a comparative evaluation.
    Dejter SW; Martin JS; McPherson RA; Lynch JH
    Urology; 1988 Oct; 32(4):288-92. PubMed ID: 2459831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum prostate-specific antigen determination in prostatic carcinoma.
    Tizzani A; Casetta G; Piana P; Bellina M; Pecchio F; Aimo G; Adamo R
    Int J Biol Markers; 1987; 2(3):184-6. PubMed ID: 2453594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen in prostatic cancer.
    Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A
    Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
    Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL
    Prostate; 1993; 23(3):201-12. PubMed ID: 7694265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.
    Fuse H; Umeda K; Mizuno I; Katayama T
    Int Urol Nephrol; 1991; 23(5):455-63. PubMed ID: 1718922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
    Guillet J; Role C; Duc AT; François H
    Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
    Pagani F; Zambolin T; Bonora R; Panteghini M
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.